Collegium Pharmaceutical, Inc.: net current accounts receivable
Net current accounts receivable for Collegium Pharmaceutical, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Collegium Pharmaceutical, Inc. financial histories
What this measure means
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
Exact concept: us-gaap:AccountsReceivableNetCurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2016-12-31 to 2025-12-31. The SEC response was captured on 2026-09-20.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 211,328,000 | USD | 2026-02-26 | 10-K · 0001628280-26-011992 |
| At date | 2024-12-31 | 228,540,000 | USD | 2026-02-26 | 10-K · 0001628280-26-011992 |
| At date | 2023-12-31 | 179,525,000 | USD | 2025-02-27 | 10-K · 0001558370-25-001801 |
| At date | 2022-12-31 | 183,119,000 | USD | 2024-02-22 | 10-K · 0001558370-24-001526 |
| At date | 2021-12-31 | 105,844,000 | USD | 2023-02-23 | 10-K · 0001558370-23-001900 |
| At date | 2020-12-31 | 83,320,000 | USD | 2022-02-24 | 10-K · 0001558370-22-001927 |
| At date | 2019-12-31 | 72,953,000 | USD | 2021-02-25 | 10-K · 0001558370-21-001814 |
| At date | 2018-12-31 | 77,946,000 | USD | 2020-02-27 | 10-K · 0001558370-20-001625 |
| At date | 2017-12-31 | 9,969,000 | USD | 2019-02-27 | 10-K · 0001558370-19-001187 |
| At date | 2016-12-31 | 2,129,000 | USD | 2018-03-07 | 10-K · 0001558370-18-001644 |
Related financial histories
- Collegium Pharmaceutical, Inc.: total assets
- Collegium Pharmaceutical, Inc.: total liabilities
- Collegium Pharmaceutical, Inc.: stockholders equity
- Collegium Pharmaceutical, Inc.: cash and cash equivalents
- Collegium Pharmaceutical, Inc.: net income or loss
- Collegium Pharmaceutical, Inc.: operating cash flow
- Collegium Pharmaceutical, Inc.: capital expenditure payments
- Collegium Pharmaceutical, Inc.: contract revenue excluding tax
- Collegium Pharmaceutical, Inc.: financing cash flow
- Collegium Pharmaceutical, Inc.: investing cash flow
- Collegium Pharmaceutical, Inc.: retained earnings or deficit
- Collegium Pharmaceutical, Inc.: basic weighted-average shares
- Collegium Pharmaceutical, Inc.: diluted weighted-average shares
- Collegium Pharmaceutical, Inc.: basic earnings per share
- Collegium Pharmaceutical, Inc.: diluted earnings per share
- Collegium Pharmaceutical, Inc.: income tax expense or benefit
- Collegium Pharmaceutical, Inc.: net property, plant and equipment
- Collegium Pharmaceutical, Inc.: share-based compensation expense
- Collegium Pharmaceutical, Inc.: operating income or loss
- Collegium Pharmaceutical, Inc.: current assets
- Collegium Pharmaceutical, Inc.: interest expense
- Collegium Pharmaceutical, Inc.: current liabilities
- Collegium Pharmaceutical, Inc.: current accounts payable
- Collegium Pharmaceutical, Inc.: goodwill carrying amount
- Collegium Pharmaceutical, Inc.: net finite-lived intangible assets
- Collegium Pharmaceutical, Inc.: common-stock repurchase payments
- Collegium Pharmaceutical, Inc.: operating expenses
- Collegium Pharmaceutical, Inc.: net inventory
- Collegium Pharmaceutical, Inc.: gross profit
- Collegium Pharmaceutical, Inc.: selling, general and administrative expense
- Collegium Pharmaceutical, Inc.: research and development expense
Inspect the source
- Entity
- Collegium Pharmaceutical, Inc. / CIK 0001267565
- Captured
- 2026-09-20T07:47:35.302Z
- SEC response SHA-256
55033ea34621442ccc325ee63acadd60be136d2ddc30ac1599d3241f95c4d123
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001267565.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))